russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2013-3-100-103russjcardiol-395Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWТЕРАПИЯ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ БЛОКАТОРОМ КАЛЬЦИЕВЫХ КАНАЛОВ И ИНГИБИТОРОМ АПФ. ПРЕИМУЩЕСТВА КОМБИНИРОВАННОЙ ТЕРАПИИArterial hypertension treatment with a calcium channel blocker and an ACE inhibitor. Benefits of combination therapyТаратухинЕ. О.TaratukhinE. O.

к. м.н., ассистент кафедры госпитальной терапии № 1 л/ф

cardio03@list.ruГБОУ ВПО РНИМУ им. Н. И. Пирогова, Москва, РоссияРоссияN. I. Pirogov Russian National Medical Research University, Moscow, RussiaRussian Federation20132806201303100103Copyright © Таратухин Е.О., 20132013Таратухин Е.О.Taratukhin E.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/395

В статье делается акцент на необходимости применения двойной гипотензивной терапии. Указываются особенности и преимущества такого подхода, позволяющего пользоваться не только синергизмом гипотензивного эффекта, но и целым рядом других преимуществ. Рассматривается один из наиболее патогенетически обоснованных вариантов комбинированной терапии: сочетание дигидропиридинового антагониста каналов кальция III поколения и ингибитора ангиотензин-превращающего фермента.

The paper emphases the need for dual antihypertensive therapy and describes itsbenefits, such as synergetic hypotensive action and other beneficial effects. One ofthe pathogenetically justified variants of combination therapy – a third-generationdihydropyridine calcium channel antagonist and an angiotensin-converting enzymeinhibitor – is discussed in more detail.

ренингипотензивный эффектлерканидипинэналаприлкомбинированная терапияrenninhypotensive effectlercanidipinecombination therapyReferencesMa J., Lee K. – V., Stafford R. S. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension. Hypertension. 2006; 48: 846–52.Ma J., Lee K. – V., Stafford R. S. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension. Hypertension. 2006; 48: 846–52.Katzung B. G. Basic and clinical pharmacology. 10th ed. McGrawHill. 2007; 1179c.Katzung B. G. Basic and clinical pharmacology. 10th ed. McGrawHill. 2007; 1179c.Bangalore S., Kamala G., Parker S. et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med, 2007; 120 (8):713–9.Bangalore S., Kamala G., Parker S. et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med, 2007; 120 (8):713–9.Panjabi S., Lacey M., Bancroft T. et al. Treatment adherence, clinical outcomes and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens, 2013; 7 (1):46–60.Panjabi S., Lacey M., Bancroft T. et al. Treatment adherence, clinical outcomes and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens, 2013; 7 (1):46–60.Silva P. S., Fontana V., Luizon M. R. et al. eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol. 2012; Jun, 17.Silva P. S., Fontana V., Luizon M. R. et al. eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol. 2012; Jun, 17.Cacciatore F., Bruzzese G., Vitale D. F. et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage and oxidative stress in hypertensive patients. Eur J Clin Pharmacol. 2011; 67:877–93.Cacciatore F., Bruzzese G., Vitale D. F. et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage and oxidative stress in hypertensive patients. Eur J Clin Pharmacol. 2011; 67:877–93.Velez Rueda J. O., Palomeque J., Mattiazzi A. et al. Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensinsystem activity involves CaMKII. J Appl Physiol. 2012; 112:2110–20.Velez Rueda J. O., Palomeque J., Mattiazzi A. et al. Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensinsystem activity involves CaMKII. J Appl Physiol. 2012; 112:2110–20.Hoque R., Rahman M. S., Iqbal M. et al. Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. Bangl Med Res Counc Bull. 2009; 35:44–8.Hoque R., Rahman M. S., Iqbal M. et al. Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. Bangl Med Res Counc Bull. 2009; 35:44–8.Mauer M., Zinman B., Gardiner R. et al. Renal and retinal effects of enalapril and losartan in pype 1 diabetes. N Engl J Med. 2009; 361:40–51.Mauer M., Zinman B., Gardiner R. et al. Renal and retinal effects of enalapril and losartan in pype 1 diabetes. N Engl J Med. 2009; 361:40–51.Borghi C. Lercanidipine in hypertension. Vasc Health & Risk Manag, 2005; 1: 173–82.Borghi C. Lercanidipine in hypertension. Vasc Health & Risk Manag, 2005; 1: 173–82.Minushkina L. O., Iosava I. K. Lercanidipine in arterial hypertension. Kardiologia, 2012; 52: 70–4. (Русский: Минушкина Л. О., Иосава И. К. Лерканидипин в лечении артериальной гипертензии. Кардиология, 2012; 52:70–4)Minushkina L. O., Iosava I. K. Lercanidipine in arterial hypertension. Kardiologia, 2012; 52: 70–4. (Русский: Минушкина Л. О., Иосава И. К. Лерканидипин в лечении артериальной гипертензии. Кардиология, 2012; 52:70–4)Yeh J. L., Hsu J. H., Liang J. C. et al. Lercanidipine and labedipinedilol-A attenuate lipopolysaccharideinterferon-gamma-induced inflammation in rat vascular smooth muscle cells. Atherosclerosis, 2013; 226 (2):364–72.Yeh J. L., Hsu J. H., Liang J. C. et al. Lercanidipine and labedipinedilol-A attenuate lipopolysaccharideinterferon-gamma-induced inflammation in rat vascular smooth muscle cells. Atherosclerosis, 2013; 226 (2):364–72.Sakurai-Yamashita Y., Harada N., Niwa M. Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP. Cell Mol Neurobiol, 2011; 31:561–7.Sakurai-Yamashita Y., Harada N., Niwa M. Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP. Cell Mol Neurobiol, 2011; 31:561–7.Borghi C., Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Pt Prefer Adh, 2012; 6:449–55.Borghi C., Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Pt Prefer Adh, 2012; 6:449–55.Cicero A. F., Borghi C. Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipineenalapril. Clin Drug Investig, 2010; 30 (12):843–54.Cicero A. F., Borghi C. Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipineenalapril. Clin Drug Investig, 2010; 30 (12):843–54.Gupta AK, Arshad S, Poulter NR. Compliance, Safety and Effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension, 2010; 55:399–407.Gupta AK, Arshad S, Poulter NR. Compliance, Safety and Effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension, 2010; 55:399–407.Messerli F. H. Review: fixed-dose drug combinations improve medication compliance compared with free-drug regimens. Evid Based Med, 2008; 13:18–22.Messerli F. H. Review: fixed-dose drug combinations improve medication compliance compared with free-drug regimens. Evid Based Med, 2008; 13:18–22.

The authors declare that there are no conflicts of interest present.